Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma
Reposted from JAMA Network
A new clinical study found that cabozantinib, a medication used to treat renal cell carcinoma (RCC), showed considerable intracranial activity and an acceptable safety profile in patients with brain metastases from RCC.